Abstract
The major sphingolipid metabolite, sphingosine-1-phosphate (S1P), has important biological functions. S1P is the ligand for a family of five G-protein-coupled receptors with distinct signaling pathways that regulate angiogenesis, vascular maturation, immunity, chemotaxis, and other important biological pathways. Recently, clinical trials have targeted S1P receptors (S1PRs) for autoimmune diseases and transplantation and have generated considerable interest in developing additional, more selective compounds. This review summarizes current knowledge on the biology of S1P and S1PRs that forms the basis for future drug development and the treatment of kidney disease.
Original language | English |
---|---|
Pages (from-to) | 1220-1230 |
Number of pages | 11 |
Journal | Kidney International |
Volume | 73 |
Issue number | 11 |
DOIs | |
Publication status | Published - 2008 Jun |
Externally published | Yes |
Bibliographical note
Funding Information:We gratefully acknowledge Hong Ye and Michael Rouse for expert technical assistance, Dr Timothy Macdonald (Department of Chemistry, University of Virginia) for providing VPC44116, Drs Diane L Rosin (Department of Pharmacology, University of Virginia) and Konstantine Kutshivili (Department of Medicine, University of Virginia) for careful reading of the manuscript, and Steven P Song for artwork. This work was supported by grants from the National Institutes of Health RO1 DK56223, RO1 DK62324, RO1 DK065957, and R01GM067958.
Keywords
- Acute kidney injury
- FTY720
- Ischemia-reperfusion injury
- S1P
- SEW2871
- Sphingolipid
ASJC Scopus subject areas
- Nephrology